Business
Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth.
About this update from Zomedica Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth\r\n \r\n \r\n\r\n\r\nZomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth\r\n\r\n\r\n\r\n\r\n\r\nZomedica posts highest quarterly revenue ever and record year-over-year revenue for 19th straight quarter! ANN ARBOR, MI / ACCESS Newswire / November 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) (\"Zomedica\" or the \"Company\"), an animal health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2025.\r\n \"Delivering 16% growth and achieving record year-over-year revenue for the 19th straight quarter demonstrates the consistency and resilience of our business. Crossing $8 million in quarterly sales for the first time is a proud moment for our company and a clear indicator that our long-term strategy is working\" said Larry Heaton, Chief Executive Officer of Zomedica.\r\n \"Fueled by robust demand for our PulseVet® and Assisi® therapeutic device products, continued accelerated growth and adoption of our diagnostic products, including our expanding TRUFORMA® platform, and the successful introduction of our new Development Services revenue stream, we delivered the strongest quarter in company history.\r\n \"As we continue to identify ways to leverage our infrastructure and intellectual property assets, the new Development Services business segment captures revenue we generate from providing development and engineering services along with contract manufacturing and licensing of our intellectual property. During the quarter, we booked $0.7M in revenue in this new segment, produced from our work on behalf of a company in the human health space. We are optimistic about our ability to continue to generate increasing revenue from this new segment, providing planned operating leverage.\r\n \"Ongoing portfolio expansion and optimization of our commercial organization continue to drive strong performance, as evidenced by 51% growth in our Diagnostic segment and 14% growth in total Consumable sales year-over-year. This perf...